---
pmid: '21535261'
title: 'Cdc2: a monopotent or pluripotent CDK?'
authors:
- Hu X
- Moscinski LC
journal: Cell Prolif
year: '2011'
full_text_available: false
pmcid: PMC6496858
doi: 10.1111/j.1365-2184.2011.00753.x
---

# Cdc2: a monopotent or pluripotent CDK?
**Authors:** Hu X, Moscinski LC
**Journal:** Cell Prolif (2011)
**DOI:** [10.1111/j.1365-2184.2011.00753.x](https://doi.org/10.1111/j.1365-2184.2011.00753.x)
**PMC:** [PMC6496858](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6496858/)

## Abstract

1. Cell Prolif. 2011 Jun;44(3):205-11. doi: 10.1111/j.1365-2184.2011.00753.x.

Cdc2: a monopotent or pluripotent CDK?

Hu X(1), Moscinski LC.

Author information:
(1)Department of Biology, College of Arts & Sciences, Barry University, Miami 
Shores, FL, USA. xthu@mail.barry.edu

Cell cycle progression is controlled by both extracellular and intracellular 
signalling molecules. It has been generally believed that cdc2/CDK1 only control 
G(2)-M transition in mammalian and many other higher eukaryotic cells. 
Accumulating evidence shows that cdc2 not only promotes G(2)-M transition but is 
also capable of regulating G(1) progress and G(1)-S transition via association 
with multiple interphase cyclins; cdc2 activity can be inhibited by p21 and p27, 
two traditional G(1) CDK inhibitors. In addition, cdc2-cyclin B controls 
pronuclear union in interphase fertilized eggs. These data suggest that cdc2 may 
be a pluripotent CDK. Although mechanisms responsible for the multiple functions 
of cdc2 remain to be further investigated, interactions of cdc2 with pRb and 
with several important transcription factors may provide a clue to the 
pluripotent role of cdc2.

Â© 2011 Blackwell Publishing Ltd.

DOI: 10.1111/j.1365-2184.2011.00753.x
PMCID: PMC6496858
PMID: 21535261 [Indexed for MEDLINE]
